ADC Therapeutics (ADCT) Debt to Equity: 2020-2023
Historic Debt to Equity for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to -$0.00.
- ADC Therapeutics' Debt to Equity fell 295.35% to -$0.00 in Q3 2023 from the same period last year, while for Sep 2023 it was -$2.26, marking a year-over-year decrease of 183.05%. This contributed to the annual value of $1.54 for FY2022, which is 99.73% down from last year.
- ADC Therapeutics' Debt to Equity amounted to -$0.00 in Q3 2023, which was up 84.09% from -$0.01 recorded in Q2 2023.
- ADC Therapeutics' Debt to Equity's 5-year high stood at $564.33 during Q4 2021, with a 5-year trough of -$0.01 in Q2 2023.
- Over the past 3 years, ADC Therapeutics' median Debt to Equity value was $0.37 (recorded in 2021), while the average stood at $51.66.
- Its Debt to Equity has fluctuated over the past 5 years, first spiked by 103,914.13% in 2021, then crashed by 295.35% in 2023.
- Quarterly analysis of 4 years shows ADC Therapeutics' Debt to Equity stood at $0.00 in 2020, then surged by 103,914.13% to $564.33 in 2021, then slumped by 99.73% to $1.54 in 2022, then tumbled by 295.35% to -$0.00 in 2023.
- Its last three reported values are -$0.00 in Q3 2023, -$0.01 for Q2 2023, and $0.00 during Q1 2023.